Figure 1. Putaminal tracer binding/uptake in LRRK2 mutation carriers.

The average left and right putaminal tracer binding/uptake values in LRRK2 mutation carriers are given as a fraction of age-matched healthy control values. The means with 95% confidence intervals for asymptomatic (unaffected) subjects and subjects with clinically confirmed LRRK2–Parkinson disease (PD) are also shown. Circles indicate ¹⁸F-fluoro-l-dopa (FD) uptake, triangles indicate ¹¹C-dihydrotetrabenazine (DTBZ) binding, and squares indicate ¹¹C-d-threo-methylphenidate (MP) binding.